-
BGJ398 for FGFR Signaling Research
2026-09-14
BGJ398 (NVP-BGJ398) provides a highly selective way to test FGFR1/2/3 dependence in cancer cells, signaling assays, and carefully designed developmental explant studies. This practical guide connects dose planning, pathway readouts, solubility control, and troubleshooting to improve reproducibility in oncology research.
-
Spatial Validation with the Cy3 TSA Fluorescence System Kit
2026-09-14
Spatial proteomics can reveal cell-type-specific molecular programs, but translational researchers still need sensitive, interpretable imaging to validate where selected biomolecules reside. This article explains how the Cy3 TSA Fluorescence System Kit can complement proximity proteomics through HRP-catalyzed tyramide deposition, targeted fluorescence microscopy detection, and disciplined experimental controls.
-
Fenipentol Workflows for Secretion Research
2026-09-13
Fenipentol, also called 1-Phenyl-1-pentanol, connects volatile natural-product profiling with practical secretion and cell-based assays. This guide translates docking, metabolomics, and historical pancreatobiliary findings into controlled workflows, assay choices, and troubleshooting steps without overstating translational evidence.
-
Meropenem Trihydrate: From MIC to Metabolome
2026-09-12
Meropenem trihydrate is a versatile carbapenem antibiotic for linking antibacterial activity with metabolic phenotypes. This guide presents a two-layer assay strategy grounded in recent carbapenemase-producing Enterobacterales research.
-
Nile Red: Lipid Droplet Imaging Workflow
2026-09-12
Nile Red combines membrane-sensitive red fluorescence with lipid-droplet-focused green fluorescence, giving researchers a practical route to compare lipid distribution and storage in the same sample. This workflow translates a mechanism-first, orthogonal-assay strategy from biofilm research into more reproducible lipid metabolism research without overstating what fluorescence alone can prove.
-
USP7–PKM2 Control in Severe Acute Pancreatitis
2026-09-11
A 2025 study links USP7 deubiquitination of PKM2 to glycolytic metabolic reprogramming and pro-inflammatory macrophage polarization in severe acute pancreatitis. Its combination of genetic perturbation, metabolic flux analysis, protein-interaction assays, and pharmacological rescue positions PKM2 as a mechanistic—not merely correlative—node in pancreatic inflammation.
-
MLKL Polymerization, LMP, and Necroptosis
2026-09-11
The reference study identifies lysosomal membrane permeabilization as a mechanistic step linking MLKL polymerization to necroptotic cell death. Using live-cell imaging, lysosomal tracking, and cathepsin B perturbation, it shows that MLKL-driven lysosomal damage releases cathepsin B before plasma membrane rupture and that reducing cathepsin B activity protects cells.
-
PKM2 Inhibitor 3k: From Glycolysis to Translation
2026-09-10
PKM2 inhibitor (compound 3k) offers a translational bridge between tumor metabolism and immunometabolic research. This article examines its mechanism, preclinical evidence, workflow design, competitive positioning, and the strategic questions required to advance pyruvate kinase M2 inhibition beyond a conventional product-page narrative.
-
CFDA-SE for Proliferation and Migration Tracking
2026-09-10
CFDA-SE converts intracellular esterase activity into a division-sensitive fluorescence record for viable cells, enabling quantitative proliferation and migration studies. Used alongside surface-proteome methods such as nanobody-TurboID, it separates cell behavior from the molecular neighborhoods that may regulate it.
-
NVP-BGJ398 phosphate: FGFR Research Workflow
2026-09-09
NVP-BGJ398 phosphate connects potent FGFR1–3 pathway inhibition with practical oncology, chondrocyte, and skeletal-disease workflows. This guide translates biochemical potency into stepwise assays, genotype-aware controls, and troubleshooting strategies for more reproducible translational research.
-
Lidocaine With Epinephrine Shortage: Evidence and Solutions
2026-09-09
Bodie, Brodell, and Helms analyze the persistent U.S. shortage of lidocaine with epinephrine and identify both manufacturer-level and supply-chain causes. Their practical contribution is a stewardship framework that combines lower-volume injections, reduction of avoidable vial waste, concentration adjustment, and cautious management of prepared syringes while preserving procedural quality and safety.
-
PKM2 Inhibitor (Compound 3k): Assay Logic
2026-09-08
PKM2 inhibitor (compound 3k) offers a selective way to interrogate pyruvate kinase M2, cancer metabolism, and immunometabolic signaling. This article explains how to interpret its biochemical, cellular, xenograft, and macrophage data without conflating metabolic inhibition with pathway-specific proof.
-
PKM2 inhibitor (compound 3k) Workflow Guide
2026-09-07
Build a PKM2-centered workflow that connects glycolytic flux, cancer-cell proliferation, and macrophage polarization. This guide separates product-backed benchmarks from practical starting conditions for oncology, ovarian cancer therapy, and immunometabolism experiments.
-
Ivacaftor During Prolonged Tezacaftor/Elexacaftor
2026-09-07
This in vitro study clarifies why ivacaftor can provide a net functional benefit during prolonged tezacaftor/elexacaftor exposure, despite earlier reports of reduced F508del-CFTR correction after chronic potentiator treatment. Using differentiated human nasal epithelia and Ussing chamber electrophysiology, the authors show that ivacaftor increases constitutive CFTR activity specifically in the triple-modulator context.
-
SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors
2026-09-05
The 2024 reference study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and sustains cancer stem cell-like properties in thymic epithelial tumors. Integrated genomic, functional, single-cell, chromatin, interaction, and phosphoproteomic analyses connect SNAI1 to PIK3R2, phosphorylated EphA2, and downstream GSK3β/β-catenin signaling, providing a mechanistic framework for future target validation.